Table 3.
Prevalence estimates of viral load suppression among PLHIV on ART for 12 (±3) or ≥48 months, Nicaragua, 2016a
| ADR12 | ADR48 | |||
|---|---|---|---|---|
| n/N | % (95% CI) | n/N | % (95% CI) | |
| PLHIV on ART | 86/114 | 77.8 (67.1 to 85.8) | 240/353 | 70.3 (66.7 to 73.8) |
| Male | 58/76 | 83.5 (73.8 to 90.2) | 148/219 | 68.7 (62.2 to 74.5) |
| Female | 28/38 | 66.4 (42.7 to 84.0) | 92/134 | 72.5 (65.2 to 78.8) |
| ≤25 years | 21/27 | 77.2 (45.6 to 93.2) | 11/27 | 51.5 (23.0 to 79.1) |
| >25 years | 65/87 | 78.2 (70.9 to 84.0) | 229/326 | 72.2 (68.1 to 75.9) |
| PLHIV on first‐line ART | 82/110 | 77.3 (66.4 to 85.5) | 208/303 | 70.9 (66.8 to 74.6) |
| Male | 54/72 | 83.0 (79.0 to 86.3) | 126/184 | 69.2 (63.5 to 74.3) |
| Female | 28/38 | 66.4 (45.0 to 82.7) | 82/119 | 73.2 (66.9 to 78.7) |
| ≤25 years | 21/27 | 77.2 (44.7 to 93.4) | 8/21 | 55.9 (37.7 to 72.6) |
| >25 years | 61/83 | 77.4 (70.9 to 82.8) | 200/282 | 72.3 (68.0 to 76.2) |
| PLHIV on first‐line NNRTI‐based ART | 78/104 | 80.7 (76.1 to 84.7) | 182/264 | 70.3 (65.7 to 74.4) |
| Male | 54/72 | 83.0 (79.0 to 86.3) | 112/163 | 68.9 (62.8 to 74.4) |
| Female | 24/32 | 74.7 (60.5 to 85.1) | 70/101 | 72.1 (64.7 to 78.4) |
| ≤25 years | 21/26 | 88.9 (81.2 to 93.7) | 5/16 | 33.3 (14.5 to 59.5) |
| >25 years | 57/78 | 76.8 (69.7 to 82.6) | 177/248 | 72.9 (68.2 to 77.1) |
ADR12, acquired drug resistance at 12 (±3) months on ART; ADR48, acquired drug resistance at ≥48 months on ART; ART, antiretroviral therapy; CI, confidence interval; NA, not applicable; NNRTI, non‐nucleoside reverse transcriptase inhibitor; PLHIV, people living with HIV.
a
Study design‐weighted proportions and 95% confidence intervals. VL suppression was defined as <1000 copies/mL.